RT Journal Article
T1 Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea.
A1 Alvarez-Larrán, Alberto
A1 Pérez-Encinas, Manuel
A1 Ferrer-Marín, Francisca
A1 Hernández-Boluda, Juan Carlos
A1 Ramírez, María José
A1 Martínez-López, Joaquín
A1 Magro, Elena
A1 Cruz, Yasmina
A1 Mata, María Isabel
A1 Aragües, Pilar
A1 Fox, María Laura
A1 Cuevas, Beatriz
A1 Montesdeoca, Sara
A1 Hernández-Rivas, José Angel
A1 García-Gutiérrez, Valentín
A1 Gómez-Casares, María Teresa
A1 Steegmann, Juan Luis
A1 Durán, María Antonia
A1 Gómez, Montse
A1 Kerguelen, Ana
A1 Bárez, Abelardo
A1 García, Mari Carmen
A1 Boqué, Concepción
A1 Raya, José María
A1 Martínez, Clara
A1 Albors, Manuel
A1 García, Francesc
A1 Burgaleta, Carmen
A1 Besses, Carlos
A1 Grupo Español de Neoplasias Mieloproliferativas Filadelfia Negativas, 
AB Hematocrit control below 45% is associated with a lower rate of thrombosis in polycythemia vera. In patients receiving hydroxyurea, this target can be achieved with hydroxyurea alone or with the combination of hydroxyurea plus phlebotomies. However, the clinical implications of phlebotomy requirement under hydroxyurea therapy are unknown. The aim of this study was to evaluate the need for additional phlebotomies during the first five years of hydroxyurea therapy in 533 patients with polycythemia vera. Patients requiring 3 or more phlebotomies per year (n=85, 16%) showed a worse hematocrit control than those requiring 2 or less phlebotomies per year (n=448, 84%). There were no significant differences between the two study groups regarding leukocyte and platelet counts. Patients requiring 3 or more phlebotomies per year received significantly higher doses of hydroxyurea than the remaining patients. A significant higher rate of thrombosis was found in patients treated with hydroxyurea plus 3 or more phlebotomies per year compared to hydroxyurea with 0-2 phlebotomies per year (20.5% vs. 5.3% at 3 years; P
YR 2016
FD 2016-09-29
LK https://hdl.handle.net/10668/25112
UL https://hdl.handle.net/10668/25112
LA en
DS RISalud
RD Apr 6, 2025